{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:55:39Z","timestamp":1793501739812,"version":"4.5.0"},"reference-count":45,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:00:00Z","timestamp":1718496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Advanced chronic liver disease and advanced chronic liver disease\u2010related ascites have a high mortality. The pharmacological treatment of ascites and fluid overload has changed little over time. Empagliflozin, a sodium\u2010glucose cotransporter type 2 inhibitor is an untested potential novel treatment in cirrhosis, as it has survival benefits in heart failure, which has similar pathophysiological fluid overload mechanisms. Before investigating empagliflozin's potential benefit in cirrhosis, its safety must be addressed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ten participants (five each with compensated or decompensated advanced chronic liver disease, based on Child\u2013Pugh class) received empagliflozin 10\u2009mg orally daily for 4\u2009weeks with 2\u2009weeks follow\u2010up. Empagliflozin safety, pharmacokinetics and pharmacodynamics were investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, eight patients (80%) reported an adverse event, and three patients (30%) experienced a serious adverse event, one of which was attributed to empagliflozin. Overall, the frequency of adverse events was similar to previous phase 3 trials of gliflozins. Higher plasma empagliflozin concentrations did not significantly increase the risk of adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Four\u2010week treatment with empagliflozin was safe and well tolerated in patients with advanced chronic liver disease. These preliminary data support assessment of long\u2010term treatment on disease\u2010related and mortality outcomes in patients with cirrhosis through randomized control trials.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.16139","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T05:34:10Z","timestamp":1718602450000},"page":"2529-2538","source":"Crossref","is-referenced-by-count":14,"title":["A potential novel treatment for cirrhosis\u2010related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease"],"prefix":"10.1111","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6401-4388","authenticated-orcid":false,"given":"Ivan","family":"Shen","sequence":"first","affiliation":[{"name":"University of New South Wales  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Stojanova","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology &amp; Toxicology St Vincent's Hospital  Sydney Australia"},{"name":"Faculty of Medicine University of New South Wales  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Yeo","sequence":"additional","affiliation":[{"name":"University of New South Wales  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Olsen","sequence":"additional","affiliation":[{"name":"Stats Central, Mark Wainwright Analytical Centre University of New South Wales  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Lockart","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology St Vincent's Hospital  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Wang","sequence":"additional","affiliation":[{"name":"University of New South Wales  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Roggeveld","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University Medical Centre Groningen  the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University Medical Centre Groningen  the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-0973","authenticated-orcid":false,"given":"Jerry R.","family":"Greenfield","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology St Vincent's Hospital  Sydney Australia"},{"name":"St Vincent's Clinical Campus, Faculty of Medicine University of New South Wales  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6045-6937","authenticated-orcid":false,"given":"Richard","family":"Day","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology &amp; Toxicology St Vincent's Hospital  Sydney Australia"},{"name":"St Vincent's Clinical Campus, Faculty of Medicine University of New South Wales  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Danta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology St Vincent's Hospital  Sydney Australia"},{"name":"St Vincent's Clinical Campus, Faculty of Medicine University of New South Wales  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)30925\u20109"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916\u2010014\u20100145\u2010y"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072\u2010017\u20109808\u2010z"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcm121"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.10.013"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.714"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16182"},{"issue":"2","key":"e_1_2_10_9_1","first-page":"61","article-title":"Clinical pharmacology of sodium glucose cotransporter 2 inhibitors","volume":"8","author":"Tsimihodimos V","year":"2017","journal-title":"Hellenic J Atherosclerosis"},{"issue":"4","key":"e_1_2_10_10_1","first-page":"347","article-title":"SGLT\u20102 inhibitors: the glucosuric antidiabetics","volume":"2","author":"Thaddanee R","year":"2017","journal-title":"Int J Basic Clin Pharmacol"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010013\u20100126\u2010x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12183"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2019.04.035"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174169"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_512_16"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.09.011"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261\u2010013\u20100089\u20106"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.12.013"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.364"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.06.015"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300\u2010013\u20100030\u20102"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2020.122257"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.147"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300\u2010016\u20100174\u2010y"},{"key":"e_1_2_10_31_1","unstructured":"ZinmanB WannerC LachinJM et al.BI 10773 (Empagliflozin) cardiovascular outcome event trial in type 2 diabetes mellitus patients (EMPA\u2010REG OUTCOME). (2016).https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01131676. Accessed June 1 2024."},{"key":"e_1_2_10_32_1","unstructured":"PackerM AnkerSD ButlerJ et al.EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure with reduced ejection fraction (EMPEROR\u2010reduced). (2021).https:\/\/clinicaltrials.gov\/study\/NCT03057977. Accessed June 1 2024."},{"key":"e_1_2_10_33_1","unstructured":"AnkerSD ButlerJ GerasimosF et al.EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure with preserved ejection fraction (EMPEROR\u2010preserved). (2022).https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03057951. Accessed June 1 2024."},{"key":"e_1_2_10_34_1","unstructured":"NealB PerkovicV MahaffeyKW et al.CANVAS \u2010 CANagliflozin cardioVascular assessment study (CANVAS). (2018).https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01032629. Accessed June 1 2024."},{"key":"e_1_2_10_35_1","unstructured":"PerkovicV JardineMJ NealB et al.Evaluation of the effects of Canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy (CREDENCE). (2019).https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02065791. Accessed June 1 2024."},{"key":"e_1_2_10_36_1","unstructured":"CannonCP PratleyR Dagogo\u2010JackS et al.Cardiovascular outcomes following Ertugliflozin treatment in type 2 diabetes mellitus participants with vascular disease the VERTIS CV study (MK\u20108835\u2010004). (2022).https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01986881. Accessed June 1 2024."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_10_38_1","unstructured":"McMurrayJJV SolomonSD InzucchiSE et al.Study to evaluate the effect of Dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure (DAPA\u2010HF). (2020).https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03036124. Accessed June 1 2024."},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030186"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/gox009"},{"key":"e_1_2_10_44_1","doi-asserted-by":"crossref","unstructured":"SinghV DeA AggarwalR et al.Safety and efficacy of dapagliflozin in recurrent ascites: A pilot study. (2023).","DOI":"10.21203\/rs.3.rs-4739647\/v1"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.800490"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048739"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.16139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:04:50Z","timestamp":1750305890000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.16139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,16]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/bcp.16139"],"URL":"https:\/\/doi.org\/10.1111\/bcp.16139","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,16]]}}}